ADMA — ADMA BIOLOGICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1368514 ·
Last close
$8.46
Market Cap
$1.96B
52W High
$10.65
52W Low
$7.45
ADV30
3,073,180
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 114,493,000 | 80,750,000 | 50,294,000 | 45,328,000 | 665,184,000 | 138,153,000 | 274,859,000 |
| Dec 2025 | 139,163,000 | 88,816,000 | 62,751,000 | 49,379,000 | 624,242,000 | 87,630,000 | 146,922,000 |
| Sep 2025 | 134,224,000 | 75,626,000 | 51,012,000 | 36,428,000 | 568,687,000 | 61,385,000 | 137,501,000 |
| Jun 2025 | 121,984,000 | 67,227,000 | 42,798,000 | 34,219,000 | 558,380,000 | 90,285,000 | 160,055,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$50,396,000
Investing CF
$-21,891,000
Financing CF
$-44,022,000
CapEx
$-22,891,000
Dividends Paid
—
Buybacks
$-8,902,000
EPS Diluted TTM
$0.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-161,653,000
Inventory
$206,465,000
Receivables
$158,429,000
ST Investments
—
EBIT TTM
$189,767,000
Pretax Income TTM
$182,657,000
Interest Exp TTM
$7,110,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$509,864,000
EBITDA
$214,822,000
Free Cash Flow
$58,354,124
Enterprise Value
$43,708,342,272
Total Cash
$55,921,152,000
Total Debt
$97,668,702,208
Shares Out
231,772,715
Trailing EPS
$0.68
Book Value
$1.68
ROE
43.3%
ROA
22.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 510,173,000 | 191,443,000 | 146,930,000 | 624,242,000 | 146,922,000 | — | 50,396,000 |
| Dec 2024 | 426,454,000 | 138,983,000 | 197,673,000 | 488,678,000 | 139,660,000 | — | 118,672,000 |
| Dec 2023 | 258,215,000 | 21,632,000 | -28,239,000 | 329,182,000 | 193,976,000 | — | 8,800,000 |
| Dec 2022 | 154,080,000 | -39,365,000 | -65,904,000 | 348,461,000 | 196,487,000 | — | -59,508,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.98
Max Pain — expiry 2026-08-21
max pain strike: $9.00 · spot: $8.46 · call oi: 8,586 · put oi: 4,821
Expected Move to 2026-08-21:
±$1.45
(17.14%) —
implied range
$7.01 –
$9.91
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MESO | MESOBLAST LTD | $1.84B | $14.17 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.82B | $4.07 | — |
| MEOBF | MESOBLAST LTD | $2.20B | $1.70 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.22B | $47.55 | — |
| IMCR | Immunocore Holdings plc | $1.72B | $33.81 | — |
News headlines (Yahoo Finance, 1h cache)
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
2026-07-31 21:45 · Yahoo
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
2026-07-29 13:30 · Yahoo
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-29 11:00 · Yahoo
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
2026-07-27 21:50 · Yahoo
ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations
2026-07-15 18:13 · Yahoo
ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run
2026-07-15 07:16 · Yahoo
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
2026-07-13 21:50 · Yahoo
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
2026-07-13 13:30 · Yahoo
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
2026-07-09 17:34 · Yahoo
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
2026-07-08 18:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.